Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
Département de Biologie Médicale, Centre Scientifique de Monaco, 98000 Monaco, Monaco
Institute for Research on Cancer and Aging of Nice, Centre Antoine Lacassagne, CNRS UMR 7284 and INSERM U1081, University Côte d’Azur, 06200 Nice, France
Author to whom correspondence should be addressed.
Cancers 2020, 12(4), 821; https://doi.org/10.3390/cancers12040821
Received: 21 February 2020 / Revised: 3 March 2020 / Accepted: 5 March 2020 / Published: 29 March 2020
(This article belongs to the Special Issue Cancer Molecular Imaging)
Breast cancer is the most common malignancy in women throughout the world. Metastatic dissemination to vital organs is the leading cause of breast cancer-related deaths. The treatment of metastases is mainly based on the primary tumor characteristics. However, breast cancer metastases exhibit high heterogeneity leading to different prognosis and therapeutic responses. Getting access to phenotype of metastases would allow better management of patients. The advent of theranostics in nuclear medicine has opened new opportunities for the diagnosis and treatment of cancer patients. The aim of this review is to provide an overview of current knowledge and future directions in nuclear medicine for therapeutic management of metastatic breast cancer patients.